Wanbury Ltd. | Income Statement

Fiscal year is April-March. All values INR Millions.
2013
2015
2016
2017
2018
Sales/Revenue
4,526
4,931
4,162
4,311
3,742
Cost of Goods Sold (COGS) incl. D&A
3,802
3,592
3,079
3,286
2,717
Gross Income
724
1,339
1,083
1,024
1,025
SG&A Expense
1,332
998
861
969
1,802
EBIT
610
269
-
85
778
Unusual Expense
-
1
1
-
-
Non Operating Income/Expense
82
185
3
72
761
Interest Expense
372
372
319
209
307
Pretax Income
871
88
71
46
324
Income Tax
1
25
-
4
4
Consolidated Net Income
872
63
71
51
320
Net Income
872
63
71
51
320
Net Income After Extraordinaries
872
63
71
51
320
Net Income Available to Common
872
63
71
51
320
EPS (Basic)
50.19
3.15
3.58
2.47
13.49
Basic Shares Outstanding
17
20
20
20
-
EPS (Diluted)
50.19
3.15
3.58
2.47
-
Diluted Shares Outstanding
17
20
20
20
-
EBITDA
384
365
334
189
675
Other Operating Expense
2
72
22
30
-
Non-Operating Interest Income
29
6
6
5
-

About Wanbury

View Profile
Address
BSEL Techpark, B-Wing, Sector 30-A
Mumbai Maharashtra 400703
India
Employees -
Website http://www.wanbury.com
Updated 09/14/2018
Wanbury Ltd. engages in the business of pharmaceutical and related activities, including research. The company focuses on orthopedics, gastrointestinal, gynecology and surgery therapeutic segments. The company was founded in 1990 and is headquartered in Mumbai, India.